Inventor
KIM MAENGSUP
CN11 patents
⚠️ This page may combine multiple inventors who share the name “KIM MAENGSUP”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BEIJING HANMI PHARMACEUTICAL CO LTD
10 patentsUS10273242B2Apr 30, 2019
Compound inhibiting activities of BTK and/or JAK3 kinases
BEIJING HANMI PHARMACEUTICAL CO LTD6 citations80
US9840517B2Dec 12, 2017
Compound inhibiting activities of BTK and/or JAK3 kinases
BEIJING HANMI PHARMACEUTICAL CO LTD12 citations80
US11319378B2May 3, 2022
Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
BEIJING HANMI PHARMACEUTICAL CO LTD3 citations70
US11498977B2Nov 15, 2022
Heterodimeric immunoglobulin constructs and preparation methods thereof
BEIJING HANMI PHARMACEUTICAL CO LTD2 citations68
US10562902B2Feb 18, 2020
IRAK4 inhibitor and use thereof
BEIJING HANMI PHARMACEUTICAL CO LTD2 citations64
US11827697B2Nov 28, 2023
Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof
BEIJING HANMI PHARMACEUTICAL CO LTD1 citations54
US11739151B2Aug 29, 2023
Anti-PD-L1/anti-CD47 bispecific antibody
BEIJING HANMI PHARMACEUTICAL CO LTD0 citations49
US12325743B2Jun 10, 2025
Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor
BEIJING HANMI PHARMACEUTICAL CO LTD0 citations44
US10988482B2Apr 27, 2021
IRAK4 inhibitor and use thereof
BEIJING HANMI PHARMACEUTICAL CO LTD0 citations41
US10322108B2Jun 18, 2019
N-benzoate group substituted benzopyrroline-2-one derivative and use thereof
BEIJING HANMI PHARMACEUTICAL CO LTD0 citations39